Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073177 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 819
- Enrollment target
NCT00073177: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00073177 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 819 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073177, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 819 participants
- Enrollment target
Study Summary
The aim of the study is to compare the effects of oral roflumilast with placebo on lung function in patients with asthma.
Interventions
- DRUG Roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 819 participants |
| Start Date | 2003-11 |
| Phase | Phase 3 |
What the finished NCT00073177 record still lists
NCT00073177 is an interventional study that assigns participants to a tested intervention. The registered 819 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Roflumilast is the first listed.
NCT00073177 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00073177 about?
NCT00073177 is a clinical study titled "Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)". The aim of the study is to compare the effects of oral roflumilast with placebo on lung function in patients with asthma.
What is the current status of trial NCT00073177?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 819 participants. The study started on 2003-11.
What interventions are being tested in trial NCT00073177?
The interventions under investigation include: Roflumilast (DRUG).
Who is sponsoring clinical trial NCT00073177?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00073177's enrollment target sits among peer trials
819 405th of 2000 higher than 1,596 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
- NCT04910269 · 820 participants · Phase 3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia